Story

RBC Capital Adds Canadian National Railway, Apotex, Lonza to Top 30 Global Stocks List

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
RBC Capital Adds Canadian National Railway, Apotex, Lonza to Top 30 Global Stocks List
Text size
Background

RBC Capital has updated its influential "Top 30 Global Ideas" list, adding three new companies and removing three others based on assessments of long-term upside potential. The latest quarterly refresh introduces Canadian National Railway, Apotex Health, and Lonza to the high-conviction portfolio.

Quarterly Changes and Performance

The three new additions from the Industrials and Health Care sectors replace Alcon, Boston Scientific, and DuPont de Nemours, which were removed from the list. The other 27 positions were maintained from the previous quarter, according to the report led by RBC's Co-Heads of Global Research, Graeme Pearson and Mark Odendahl.

In the second quarter of 2026, the Top 30 list delivered a total return of 11.1% in U.S. dollar terms, underperforming the MSCI World Index's 12.8% return for the same period. However, since its inception at the end of 2019, the list has generated a compound annual return of 13.9%, slightly ahead of the benchmark’s 13.4%.

Sample IUX Markets – In-articleAd

Rationale for New Selections

RBC provided its investment thesis for each of the new additions, highlighting specific catalysts and valuation metrics.

  • Canadian National Railway (CNR): The firm noted that the railroad operator trades at a discount to its peers despite improving network fundamentals. RBC cited accelerating car velocity, record grain volumes, and pricing power as key drivers for a solid earnings growth outlook.
  • Apotex Health (APTX): As a generics company with a 23% market share in Canada and a top-10 position in the U.S., Apotex is positioned to capture value from an increasing number of brand-name drugs facing loss of exclusivity. This is expected to support industry-high returns on invested capital.
  • Lonza (LONN): The Swiss life sciences firm is described as an "earnings-per-share compounder" trading at an attractive valuation relative to its growth profile. RBC analysts believe the market continues to misprice historical concerns, and the lack of immediate catalysts creates an entry point for investors with longer-term horizons.

Read next

More on Stocks
Back to latest news

LATEST